A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: The oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2)

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 8, 2015, Pages 1405-1413

  Lip, G Y H ^a   Halperin, J L ^b   Petersen, P ^c   Rodgers, G M ^d   Pall, D ^e   Renfurm, R W ^f,g  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c University of Copenhagen   (Denmark)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF DEBRECEN   (Hungary)

^f Astellas Pharma Global Development   (Netherlands)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulants; Atrial fibrillation; Clinical trial; Hemorrhage; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; D DIMER; DAREXABAN; GAMMA GLUTAMYLTRANSFERASE; WARFARIN; ANTICOAGULANT AGENT; AZEPINE DERIVATIVE; BENZAMIDE DERIVATIVE; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; BILIRUBIN BLOOD LEVEL; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPROTECTION; NON VALVULAR ATRIAL FIBRILLATION; OVARY CANCER; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DOWN REGULATION; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK FACTOR; STROKE; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; AZEPINES; BENZAMIDES; BIOMARKERS; DOUBLE-BLIND METHOD; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; FACTOR XA INHIBITORS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84937966651     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13025     Document Type: Article

References (23)

1. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-107.
2. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI, European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart D. General mechanisms of coagulation and targets of anticoagulants (Section I) position paper of the esc working group on thrombosis-task force on anticoagulants in heart disease. Thromb Haemost 2013; 109: 569-79.
3. Groenendaal D, Strabach G, Garcia-Hernandez A, Kadokura T, Heeringa M, Mol R, Eltink C, Onkels H. The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4. Br J Clin Pharmacol 2013; 75: 440-9.
4. Kadokura T, Groenendaal D, Heeringa M, Mol R, Verheggen F, Garcia-Hernandez A, Onkels H. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin. Eur J Drug Metab Pharmacokinet 2014; 39: 1-9.
5. Kadokura T, Kashiwa M, Groenendaal D, Heeringa M, Mol R, Verheggen F, Garcia-Hernandez A, Onkels H. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects. Biopharm Drug Dispos 2013; 34: 431-41.
6. Kadokura T, Taniuchi Y, Inoue H, Saito M, Iwahana M, Yamada S, Urae A, Nakamura M. Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects. Int J Clin Pharmacol Ther 2013; 51: 200-6.
7. Groenendaal D, Heeringa M, Kadokura T, Verheggen F, Strabach G, Heinzerling H. YM150, an oral direct inhibitor of factor Xa, demonstrated a predictable and dose-proportional pharmacokinetic/pharmacodynamic profile after single and multiple dosing: results from three studies. Blood 2010; 116: 3323.
8. Iwatsuki Y, Sato T, Moritani Y, Shigenaga T, Suzuki M, Kawasaki T, Funatsu T, Kaku S. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. Eur J Pharmacol 2011; 673: 49-55.
9. Hashimoto T, Suzuki K, Kihara Y, Iwatsubo T, Miyashita A, Heeringa M, Onkels H, Groenendaal D, Verheggen F, van Marle S, Usui T. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans. Xenobiotica 2013; 43: 534-47.
10. Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kalebo P, Gaillard ML, Meems L, Group O. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost. 2007; 5: 1660-5.
11. Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kalebo P, Wetherill G, Wilpshaar JW, Meems L, Onyx-2 Study G. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 2010; 8: 714-21.
12. Sakon M, Nakamura M. Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: phase III randomized, mechanical prophylaxis-controlled, open-label study. Thromb Res 2012; 130: e52-9.
13. Fuji T, Nakamura M, Takeuchi M. Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery: results from 2 randomized, placebo-controlled, double-blind studies. Clin Appl Thromb Hemost 2014; 20: 199-211.
14. Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB, Investigators R-. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011; 32: 2541-54.
15. Turpie AG, Lip GHY, Minematsu K, Goto S, Renfurm RW, Wong KSL. Safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation: a Phase II Study. Eur Heart J 2010; 31: 173.
16. Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003; 146: 431-8.
17. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9.
18. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 1419-26.
19. Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, Investigators S. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006; 152: 967-73.
20. Lane DA, Kamphuisen PW, Minini P, Buller HR, Lip GY. Bleeding risk in patients with atrial fibrillation: the AMADEUS study. Chest 2011; 140: 146-55.
21. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE, Kober L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-41.
22. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104: 633-41.
23. Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Wahlander KF, Steering C. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009; 30: 2897-907.